IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

Arun has over 15 years’ experience covering the Technology sector. During this time, he has worked with technology start-ups and as an equity analyst in investment banks and independent research firms. He was formerly a Technology Analyst for Canaccord Genuity, Altium Securities, Espirito Santo Investment Bank, Noble Group and Clear Capital. He has a dual Master’s degree in Financial Engineering and Industrial and Operations Engineering from the University of Michigan. He obtained his Bachelor’s degree in Mechanical Engineering from the Indian Institute of Technology, Bombay. He is also a CFA charterholder.

IPOs and Catalysts/Events

Mayne Pharma (MYX AU): High Risk/Reward as an FDA Letter Causes a Tailspin

Mayne Pharma (MYX AU): The Scheme Booklet Should Calm Nerves

Merger Arb Mondays (19 May) - Seven & I, Nissin, Welcia/Tsuruha, Mayne, ESR, OneConnect, Frasers

Mayne Pharma (MYX AU): Cosette Pharma’s Binding Offer at A$7.40

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Event-Driven

<ul>
<li>On Monday, President Trump signed an executive order requiring drugmakers to start offering US patients the lowest price for a drug in a peer country (the Most Favoured Nation price).</li>
<li>
<a href="https://www.smartkarma.com/entities/mayne-pharma-group-ltd" target="_blank" data-smartkarma-citation="entities:757:1" rel="noopener">Mayne Pharma (MYX AU)</a> is exposed as US accounts for 84% of revenue. I estimate that the average price reduction should be &lt;16% so that the MAC is not triggered.  </li>
<li>However, the MAC is not triggered if it arises<em> "from any change in any law, regulation or rule of a Government Agency</em>”, which should capture the Trump order.</li>
</ul>


On Monday, President Trump signed an executive order requiring drugmakers to start offering US patients the lowest price for a drug in a peer country (the Most Favoured Nation price).

Mayne Pharma (MYX AU) is exposed as US accounts for 84% of revenue. I estimate that the average price reduction should be &lt;16% so that the MAC is not triggered.  
However, the MAC is not triggered if it arises "from any change in any law, regulation or rule of a Government Agency”, which should capture the Trump order.


Mayne Pharma (MYX AU): Trump’s Executive Order Unlikely to Trigger the MAC Clause